Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Asthma control
See how Relvar can help achieve asthma control
Adherence
A treatment is only effective if a patient takes it. When it comes to Relvar, a significantly greater proportion of patients adhere to their treatment, leading to higher persistence rates with Relvar at 12 months, vs both BUD/Form and BDP/Form.*1
This graph has been independently created by GSK from the original data. The same results were first published in Parimi M, et al. Adv Ther 2020;37:2916–2931.
This graph has been independently created by GSK from the original data. The same results were first published in Parimi M, et al. Adv Ther 2020;37:2916–2931.
This graph has been independently created by GSK from the original data. The same results were first published in Parimi M, et al. Adv Ther 2020;37:2916–2931.
This graph has been independently created by GSK from the original data. The same results were first published in Parimi M, et al. Adv Ther 2020;37:2916–2931.
Patients initiating FF/VI had a 35% and 31% lower risk of discontinuing treatment compared with BUD/Form and BDP/Form respectively within 1 year after initiation (both p<0.001)1
Discover Relvar
Good adherence and quality of life
Good adherence can mean more symptom-free days and improved quality of life, with more stamina for everyday activities.2 See how else Relvar can help your patients.
Footnotes
*The primary endpoint for this study was persistence measured as time to discontinuation. FF/VI had notably less follow-up time available than comparators due to different launch dates and their consequent availability. Respective unadjusted median time to discontinuation and median follow-up time for each comparison were as follows: 99 and 393 days for FF/VI vs 116.5 and 817 days for BUD/Form; and 97 and 402 days for FF/VI vs 91 and 539 days for BDP/Form. This was a retrospective UK database study in the THIN (The Health Improvement Network) dataset. The primary endpoint was to compare persistence (time to discontinuation) for patients initiating Relvar (n=966), BUD/Form (n=5931) or BDP/Form (n=9607). Adherence was defined as the average percentage of days covered (PDC) over 12 months. ‘Good adherence’ refers to the percentage of patients achieving a PDC ≥80%. The percentage PDC is calculated using the formula: (number of days covered) / (total number days in period) × 100, where “covered” means that the patient had a corresponding filled prescription for that day.1
Abbreviations
AE, adverse event; BDP, beclomethasone dipropionate; BUD, budesonide; CI, confidence interval; FF, fluticasone furoate; Form, formoterol; OR, odds ratio; PDC, percentage of days covered; THIN, The Health Improvement Network; VI, vilanterol.
Relvar Safety Information3
Contraindications
Hypersensitivity to the active substances or to any of the excipients.
Undesirable effects
Very Common: Headache, Nasopharyngitis.
Common: Infections and infestations, Oropharyngeal pain, Sinusitis, Pharyngitis, Rhinitis, Cough, Dysphonia, Abdominal pain, Arthralgia, Back pain, Fractures, Muscle spasms and Pyrexia.
References
- Parimi M, et al. Adv Ther 2020;37:2916–2931.
- Halterman JS, et al. J Asthma 2011;48:523–530.
- Relvar Prescribing Information.
GSK does not recommend, endorse, or accept liability for the 3rd party sites.
For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
Gulf.ProductQualityComplaints@gsk.com
Department of Pharmacovigilance & Drug Information |
دائرة التيقظ و المعلومات الدوائية مركز سلامة الدواء وزارة الصحة, سلطنة عمان هاتف: 0096822357687 / 0096822357690 0096822358489 :فاكس pharma-vigil@moh.gov.om :البريد االكتروني https://moh.gov.om/en/ : الموقع االكتروني |
Trademarks are owned by or licensed to the GSK group of companies
PM-RCH-FFV-WCNT-250001 Date of preparation: July 2025
